Most studies have focused on pathways modulating cancer cell sensitivity, such as the transmembrane ATP-dependent efflux pump P-glycoprotein (P-gp) [3–6], Her-2/ERBB2 [7], the Bcl-2 family proteins [8], and, more recently, miRNAs [9, 10]. The gene discussed is ERBB2; the disease is cancer.